Solasia Pharma K.K., of Tokyo, said it started an Asian multinational phase II study of an intravenous version of SP-02 (darinaparsin, SP-02L), a mitochondrial-targeted agent, for the treatment of relapsed and refractory peripheral T-cell lymphoma. The single-arm, open-label, nonrandomized study is being conducted in Japan, South Korea, Taiwan and Hong Kong to evaluate the efficacy and safety of SP-02L monotherapy.